Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Cytoreductive treatment strategies for de novo metastatic prostate cancer.

Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU.

Nat Rev Clin Oncol. 2019 Nov 11. doi: 10.1038/s41571-019-0284-3. [Epub ahead of print] Review.

PMID:
31712648
2.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
3.

Role of radical prostatectomy in metastatic prostate cancer: A review.

Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF.

Urol Oncol. 2017 Apr;35(4):125-134. doi: 10.1016/j.urolonc.2017.01.001. Epub 2017 Feb 9. Review.

PMID:
28190749
4.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

5.

Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.

Heidenreich A, Pfister D, Porres D.

J Urol. 2015 Mar;193(3):832-8. doi: 10.1016/j.juro.2014.09.089. Epub 2014 Sep 22.

PMID:
25254935
6.

Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysis.

Zhang Q, Cheng H, Wang Y, Tian Y, Xia J, Wang Y, Zhou X, Meng X, Wang Y, Gu M, Song N.

Int J Surg. 2019 Jun;66:28-36. doi: 10.1016/j.ijsu.2019.04.006. Epub 2019 Apr 17.

PMID:
31002882
7.

[Radical cancer surgery of renal cell and prostate carcinoma with hematogenous metastasis: benefits].

Heidenreich A, Pfister D, Porres D.

Urologe A. 2014 Jun;53(6):823-31. doi: 10.1007/s00120-014-3519-z. Review. German.

PMID:
24824471
8.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
9.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
10.

Cytoreductive prostatectomy in metastatic prostate cancer: current knowledge and future directions.

Polotti CF, Sterling JA, Kim IY.

Am J Clin Exp Urol. 2019 Apr 25;7(2):80-84. eCollection 2019. Review.

11.

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.

Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ.

Eur Urol Oncol. 2018 May;1(1):46-53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15.

PMID:
31100228
12.

Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy?

Marenco J, Sooriakumaran P.

Arch Esp Urol. 2019 Mar;72(2):174-181. Review.

PMID:
30855019
13.

[Primary Tumour Treatment in Patients with Metastatic Prostate Cancer].

Steuber T, Beyer B.

Aktuelle Urol. 2016 Sep;47(5):388-94. doi: 10.1055/s-0042-113547. Epub 2016 Sep 28. Review. German.

PMID:
27680190
14.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
15.

[Radiotherapy for local disease in metastatic prostate cancer.]

Cambeiro M, Calvo FA.

Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish.

PMID:
29633951
16.

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.

Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G.

Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25.

PMID:
30266309
17.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

18.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2018 Mar;199(3):726-733. doi: 10.1016/j.juro.2017.09.033. Epub 2017 Sep 12.

PMID:
28916273
19.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
20.

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer.

Miura Y, Horie S.

ESMO Open. 2019 Mar 12;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471. eCollection 2019. Review.

Supplemental Content

Support Center